Cemiplimab
Class
Targeted therapy
Subclass
Anti-PD-1 monoclonal antibodies
Substance name
Cemiplimab, cemiplimab-rwlc
Brand names
Libtayo®
Common formulations
Solution for injection
Dosage and administration
Adults patients
Basal cell carcinoma • Locally advanced or metastatic, if hedgehog pathway inhibitors is ineffective or contraindicated
Cutaneous SCC • Locally advanced or metastatic
Non-small cell lung cancer without EGFR mutation, ALK gene fusion, NPM-ALK fusion protein, ROS1 gene fusion, ROS1 fusion protein • Locally advanced or metastatic
Non-small cell lung cancer without EGFR mutation, ALK gene fusion, NPM-ALK fusion protein, ROS1 gene fusion, ROS1 fusion protein • Locally advanced or metastatic, high PD-L1 expression
Cervical cancer • Metastatic or recurrent • Off-label
Indications for use
Labeled indications
Adults
Off-label indications
Adults
Safety risks
Contraindications
Hypersensitivity to cemiplimab or its components
Warnings and precautions
GvHD, hepatic veno-occlusive disease
Immune-related adverse events
Infusion-related reactions
Specific populations
Renal impairment
eGFR 0-90 mL/min/1.73 m²
Renal replacement therapy
Any modality
Hepatic impairment
Any severity
Pregnancy and breastfeeding
Pregnancy
All trimesters • Australia Category: D
Breastfeeding
Halt breastfeeding temporarily.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
Common 1-10%
Uncommon < 1%
Unknown frequency
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource